

Title (en)
ANGIOGENESIS INHIBITORS, COMPOSITIONS CONTAINING SAME AND USE THEREOF FOR TREATING DISEASES RELATED TO ANGIOGENETIC DEREGULATION

Title (de)
ANGIOGENESEINHIBITOREN, DIESE ENTHALTENDE ZUSAMMENSETZUNGEN UND DEREN VERWENDUNG ZUR BEHANDLUNG VON MIT DER ANGIOGENETISCHEN DEREGULATION IN ZUSAMMENHANG STEHENDEN ERKRANKUNGEN

Title (fr)
INHIBITEURS DE L'ANGIOGENESE, COMPOSITIONS LES CONTENANT ET LEUR UTILISATION POUR LE TRAITEMENT DES MALADIES LIEES A UNE DEREGULATION DE L'ANGIOGENESE

Publication
EP 1711521 A1 20061018 (FR)

Application
EP 05717534 A 20050202

Priority

- FR 2005000222 W 20050202
- FR 0400964 A 20040202
- FR 0405954 A 20040602

Abstract (en)
[origin: WO2005075509A1] The invention concerns a peptide molecule capable of interfering with the HLH domain of TAL-1, consisting of or comprising at least 10 successive amino acids and preferably at least 15 successive amino acids of the HLH domain of TAL-1 of sequence: QQNVNGAFAELRKLIPTHTPPDKKLSKNEILRLAMKYINFLA corresponding to SEQ ID No. 1 whereof the listing of sequences is annexed or an equivalent sequence, said molecule being advantageously associated with a vector. The invention also concerns a pharmaceutical composition containing said peptide molecule and the use of a compound capable of interacting with the HLH domain of TAL-1 for preparing a medicine designed for the prevention and/or treatment of diseases related to angiogenesis, preferably the treatment of cancers, arteriosclerosis and diabetes. The invention further concerns a method for identifying a biologically active compound capable of being used in the prevention and/or treatment of diseases related to angiogenesis, preferably the treatment of cancers, arteriosclerosis and diabetes which consists in detecting inhibition of the interaction between the HLH domain of TAL-1 and its partner E47 in the presence of said compound.

IPC 8 full level
C07K 14/47 (2006.01); **C12N 15/62** (2006.01); **G01N 33/50** (2006.01)

CPC (source: EP US)
A61P 3/10 (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **C07K 14/4703** (2013.01 - EP US); **C07K 2319/01** (2013.01 - EP US)

Citation (search report)
See references of WO 2005075509A1

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)
FR 2865736 A1 20050805; FR 2865736 B1 20060714; AU 2005210063 A1 20050818; CA 2554822 A1 20050818; EP 1711521 A1 20061018; JP 2008505848 A 20080228; US 2007161553 A1 20070712; WO 2005075509 A1 20050818

DOCDB simple family (application)
FR 0405954 A 20040602; AU 2005210063 A 20050202; CA 2554822 A 20050202; EP 05717534 A 20050202; FR 2005000222 W 20050202; JP 2006550249 A 20050202; US 58787405 A 20050202